Lambert JM, Chari RV (2014) Ado-trastuzumab Emtansine (T-DM1): an antibody–drug conjugate (ADC) for HER2-positive breast cancer. ACS Publications

Google Scholar 

Pondé N, Aftimos P, Piccart M (2019) Antibody-drug conjugates in breast cancer: a comprehensive review. Curr Treat Options Oncol 20(5):37

Article  PubMed  Google Scholar 

Beck A, Goetsch L, Dumontet C, Corvaïa N (2017) Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 16(5):315–337

Article  CAS  PubMed  Google Scholar 

Donaghy H (2016) Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 8(4):659–671

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jain N, Smith SW, Ghone S, Tomczuk B (2015) Current ADC linker chemistry. Pharm Res 32(11):3526–3540

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chari RV (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41(1):98–107

Article  CAS  PubMed  Google Scholar 

Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM (2014) Antibody–drug conjugates: current status and future directions. Drug Discovery Today 19(7):869–881

Article  CAS  PubMed  Google Scholar 

Sievers EL, Linenberger M (2001) Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol 13(6):522–527

Article  CAS  PubMed  Google Scholar 

Beck A, Haeuw J-F, Wurch T, Goetsch L, Bailly C, Corvaïa N (2010) The next generation of antibody-drug conjugates comes of age. Discov Med 10(53):329–339

PubMed  Google Scholar 

Chen RW, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Kennedy DA et al (2011) Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). J Clin Oncol 29(15):8031–8031

Article  Google Scholar 

Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V (2013) Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31(9):1157–1163

Article  CAS  PubMed  Google Scholar 

Tsuchikama K, An Z (2018) Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 9(1):33–46

Article  CAS  PubMed  Google Scholar 

Afzal F, Aiman W, Zahoor H, Bajwa AR, Kazmi SH, Anwar A, Anwar MY, Rashid S, Zubair H, Kashif T et al (2023) Efficacy and safety of antibody-drug conjugates in triple-negative and HER-2 positive breast cancer: a systematic review and meta-analysis of clinical trials. Breast Dis 42(1):121–136

Article  PubMed  Google Scholar 

Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A (2023) Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov 2:2

Google Scholar 

Hafeez U, Parakh S, Gan HK, Scott AM (2020) Antibody-drug conjugates for cancer therapy. Molecules 25:20

Article  Google Scholar 

Senter PD, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30(7):631–637

Article  CAS  PubMed  Google Scholar 

Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX et al (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28(16):2698–2704

Article  CAS  PubMed  Google Scholar 

Nicolo E, Zagami P, Curigliano G (2020) Antibody-drug conjugates in breast cancer: the chemotherapy of the future? Curr Opin Oncol 32(5):494–502

Article  CAS  PubMed  Google Scholar 

Wynne J, Wright D, Stock W (2019) Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv 3(1):96–104

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G et al (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7(6):1490–1496

CAS  PubMed  Google Scholar 

Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ Jr, Vahdat LT, Thomas SS, Govindan SV, Maliakal PP, Wegener WA et al (2015) First-in-human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res 21(17):3870–3878

Article  CAS  PubMed  PubMed Central  Google Scholar 

Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Hoos A, Gupta I, Bragulat V et al (2019) Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J 9(4):37

Article  PubMed  PubMed Central  Google Scholar 

Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP et al (2012) Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol 158(6):727–738

Article  CAS  PubMed  Google Scholar 

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O’Shaughnessy J, Kalinsky K, Guarino M et al (2017) Efficacy and safety of anti-trop-2 antibody drug conjugate Sacituzumab Govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol 35(19):2141–2148

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weiss J, Glode A, Messersmith WA, Diamond J (2019) Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer. Expert Rev Anticancer Ther 19(8):673–679

Article  CAS  PubMed  Google Scholar 

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O’Shaughnessy J, Moroose RL, Santin AD, Abramson VG et al (2019) Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med 380(8):741–751

Article  CAS  PubMed  Google Scholar 

Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB et al (2021) Sacituzumab Govitecan in metastatic triple-negative breast cancer. N Engl J Med 384(16):1529–1541

Article  CAS  PubMed  Google Scholar 

Bardia A, Hurvitz SA, Rugo HS, Brufsky A, Cortes J, Loibl S, Piccart M, Cowden J, Spears P, Carey LA (2021) A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. Future Oncol 17(30):3911–3924

Article  CAS  PubMed  Google Scholar 

Rizzo A, Cusmai A, Acquafredda S, Rinaldi L, Palmiotti G (2022) Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential. Expert Opin Investig Drugs 8:1–4

Google Scholar 

Taylor KM, Hiscox S, Nicholson RI (2004) Zinc transporter LIV-1: a link between cellular development and cancer progression. Trends Endocrinol Metab 15(10):461–463

Article  CAS  PubMed  Google Scholar 

Huber MA, Kraut N, Beug H (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17(5):548–558

Article  CAS  PubMed  Google Scholar 

Modi S, Pusztai L, Forero A, Mita M, Miller K, Weise A, Krop I, Burris H III, Kalinsky K, Tsai M et al (2018) Abstract PD3–14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer. Cancer Res 78:4

Article  Google Scholar 

Tsai M, Han H, Montero A, Tkaczuk K, Assad H, Pusztai L, Hurvitz S, Wilks S, Specht J, Nanda R (2021) 259P Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer. Ann Oncol 32:S474–S475

Article  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9–20

Article  CAS  PubMed  PubMed Central  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2:2

Google Scholar 

Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, Lecesne A (2023) Mechanisms of resistance to antibody-drug conjugates. Int J Mol Sci 24:11

Article  Google Scholar 

Yang R, Li Y, Wang H, Qin T, Yin X, Ma X (2022) Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. Mol Biomed 3(1):8

Article  PubMed  PubMed Central  Google Scholar 

Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A et al (2014) PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2(4):361–370

Article  CAS  PubMed